NASDAQ:KZR - Kezar Life Sciences Stock Price, News & Analysis

$4.87
+0.04 (+0.83 %)
(As of 08/18/2019 01:00 PM ET)
Today's Range
$4.61
Now: $4.87
$5.13
50-Day Range
$4.50
MA: $6.06
$7.71
52-Week Range
$4.12
Now: $4.87
$36.33
Volume35,100 shs
Average Volume68,478 shs
Market Capitalization$93.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KZR
CUSIPN/A
CIKN/A
Phone650-822-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.94 per share

Profitability

Net Income$-23,170,000.00

Miscellaneous

Employees24
Market Cap$93.21 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive KZR News and Ratings via Email

Sign-up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.


Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences Inc (NASDAQ:KZR) posted its earnings results on Wednesday, August, 7th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02. View Kezar Life Sciences' Earnings History.

When is Kezar Life Sciences' next earnings date?

Kezar Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Kezar Life Sciences.

What price target have analysts set for KZR?

3 Wall Street analysts have issued 12-month price targets for Kezar Life Sciences' shares. Their forecasts range from $15.00 to $15.00. On average, they expect Kezar Life Sciences' share price to reach $15.00 in the next year. This suggests a possible upside of 208.0% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

What is the consensus analysts' recommendation for Kezar Life Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

Has Kezar Life Sciences been receiving favorable news coverage?

Media coverage about KZR stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kezar Life Sciences earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Kezar Life Sciences.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a decrease in short interest in July. As of July 15th, there was short interest totalling 1,117,200 shares, a decrease of 8.6% from the June 15th total of 1,222,400 shares. Based on an average daily trading volume, of 114,400 shares, the days-to-cover ratio is currently 9.8 days. Currently, 10.0% of the company's shares are sold short. View Kezar Life Sciences' Current Options Chain.

Who are some of Kezar Life Sciences' key competitors?

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Gilead Sciences (GILD), Apollo Commercial Real Est. Finance (ARI), Zoetis (ZTS), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Akorn (AKRX), Align Technology (ALGN), Amarin (AMRN), Ares Capital (ARCC) and BIOLINERX LTD/S (BLRX).

Who are Kezar Life Sciences' key executives?

Kezar Life Sciences' management team includes the folowing people:
  • Mr. John Fowler, Co-Founder, CEO & Director (Age 47)
  • Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 47)
  • Dr. Jack Taunton, Co-Founder
  • Mr. Marc L. Belsky, CFO & Sec. (Age 64)
  • Michael Wolfe, Director of Fin. & Operations

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (5.06%), BlackRock Inc. (4.41%), EcoR1 Capital LLC (3.05%), Victory Capital Management Inc. (2.41%), Vanguard Group Inc. (2.09%) and Cowen Inc. (1.79%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Morningside Venture Investment and Vassiliki Economides. View Institutional Ownership Trends for Kezar Life Sciences.

Which institutional investors are selling Kezar Life Sciences stock?

KZR stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, EcoR1 Capital LLC, Cowen Inc., Cowen Inc., Citadel Advisors LLC and Vanguard Group Inc.. View Insider Buying and Selling for Kezar Life Sciences.

Which institutional investors are buying Kezar Life Sciences stock?

KZR stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., Wells Fargo & Company MN, Bank of New York Mellon Corp, A.R.T. Advisors LLC and Acadian Asset Management LLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Morningside Venture Investment and Vassiliki Economides. View Insider Buying and Selling for Kezar Life Sciences.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $4.87.

How big of a company is Kezar Life Sciences?

Kezar Life Sciences has a market capitalization of $93.21 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.View Additional Information About Kezar Life Sciences.

What is Kezar Life Sciences' official website?

The official website for Kezar Life Sciences is http://www.kezarlifesciences.com/.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]


MarketBeat Community Rating for Kezar Life Sciences (NASDAQ KZR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote "Outperform" if you believe KZR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Featured Article: Stop Order

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel